Pharmacy

Your Article Summary

See Latest Articles

Mesalazine for ulcerative colitis: evidence for use
Nurse Prescribing, 09/02/09

Greveson K – Ulcerative colitis is a chronic, idiopathic inflammatory disease of the colon characterized by periods of exacerbation and remission. Medical treatment aims to provide rapid effective relief from symptoms, modify the disease process and improve quality of life. Many oral preparations use multiple daily dosing regimens which can be inconvenient and affect treatment adherence leading to increased morbidity and risk of symptomatic relapse. This article examines the issues surrounding the use of mesalazine in ulcerative colitis, focusing on Mezavant XL (MMX mesalazine), a once–daily dosing formulation with patented multi–matrix system.

Related Articles

See all related articles

Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis
Digestion, 10/15/09    Relevance Score: 87%

Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis
Scandinavian Journal of Gastroenterology, 11/06/09    Relevance Score: 84%

Today in Stomach/GI...keeping you current

Receive free subspecialty "5-minute updates" via email

Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
Transplant Infectious Disease, 12/11/09

A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
Alimentary Pharmacology and Therapeutics, 12/10/09

Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection
Journal of Gastroenterology, 12/10/09

 See all of Stomach/GI